Indeed, TLR9 agonists can enhance antitumor immunity by reprogramming the tumor microenvironment and increasing the tumor-suppressive potential and/or cytotoxic activity of innate and adaptive immune cells [28,29], leading to immune rejection of solid tumors [30,31,32,33]. Here, TLR9 is linked to neoplasm.